Q1 2015 13F Holders as of 3/31/2015
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
156
-
Total 13F shares, excl. options
-
12.1M
-
Shares change
-
+429K
-
Total reported value, excl. options
-
$497M
-
Value change
-
+$17.8M
-
Put/Call ratio
-
0.55
-
Number of buys
-
82
-
Number of sells
-
-62
-
Price
-
$41.17
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q1 2015
175 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q1 2015.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 156 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.1M shares
of 14.4M outstanding shares and own 83.77% of the company stock.
Largest 10 shareholders include BlackRock Fund Advisors (893K shares), WELLINGTON MANAGEMENT GROUP LLP (861K shares), LOMBARDIA CAPITAL PARTNERS LLC (739K shares), DIMENSIONAL FUND ADVISORS LP (711K shares), BTIM Corp. (700K shares), THOMPSON SIEGEL & WALMSLEY LLC (678K shares), VANGUARD GROUP INC (662K shares), BlackRock Institutional Trust Company, N.A. (531K shares), Ranger Investment Management, L.P. (413K shares), and Portolan Capital Management, LLC (364K shares).
This table shows the top 156 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.